MEDP Q4 Deep Dive: Cancellations and Metabolic Trial Mix Pressure Margins Despite Strong Growth
Medpace (NASDAQ:MEDP) Reports Bullish Q4 CY2025
Revenue of $708.5 million in the fourth quarter of 2025 increased 32.0% from revenue of $536.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.6%. ...
Earnings To Watch: Medpace (MEDP) Reports Q4 Results Tomorrow
3 Market-Beating Stocks to Consider Right Now
1 Volatile Stock with Solid Fundamentals and 2 We Avoid
2 Cash-Heavy Stocks with Promising Prospects and 1 We Find Risky
Medpace (MEDP): Buy, Sell, or Hold Post Q3 Earnings?
2 Healthcare Stocks to Keep an Eye On and 1 We Ignore